Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C5H14NO.MoS4 |
Molecular Weight | 432.54 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[S-][Mo]([S-])(=S)=S.C[N+](C)(C)CCO.C[N+](C)(C)CCO
InChI
InChIKey=NEYVHGQOGHJAAD-UHFFFAOYSA-N
InChI=1S/2C5H14NO.Mo.4S/c2*1-6(2,3)4-5-7;;;;;/h2*7H,4-5H2,1-3H3;;;;;/q2*+1;;;;2*-1
Tiomolibdic acid salt, Bis-choline tetrathiomolybdate (ATN-224, WTX-101), is under investigation as a therapy against different cancers and Wilson’s disease (WD). ATN-224 is a second-generation analog of ammonium tetrathiomolybdate. ATN-224 is a novel copper chelator. ATN-224 inhibits CuZn superoxide dismutase 1 (SOD1) leading to antiangiogenic and antitumor effects. Strategically tailoring combination regimens that include ATN-224 and target ROS may be a viable approach to advance the treatment of melanoma. ATN-224 is in phase III clinical trial for the treatment of Hepatolenticular degeneration. WTX-101 is in phase II clinical trials for the treatment of Wilson's disease. Once daily WTX-101 treatment over 24 weeks improved neurologic disease, hepatic status and copper control in newly diagnosed WD patients. WTX-101 appears well tolerated. Drug-induced, paradoxical, neurological deterioration was not observed. This compound has received orphan drug designation in both the United States and the European Union. WTX-101 was originally discovered by University of Michigan and now is being developed by Wilson Therapeutics by acquisition.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms. | 2009 May |
|
The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies. | 2013 Jul |
|
The copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphoma. | 2014 Jul |
|
Targeting antioxidants for cancer therapy. | 2014 Nov 1 |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
569516
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
||
|
FDA ORPHAN DRUG |
346511
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
||
|
NCI_THESAURUS |
C471
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
||
|
FDA ORPHAN DRUG |
733720
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/12/1089
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID301031607
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
PRIMARY | |||
|
SUB182753
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
PRIMARY | |||
|
FD57A79R4P
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
PRIMARY | |||
|
649749-10-0
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
PRIMARY | |||
|
GH-166
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
PRIMARY | |||
|
18442052
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
PRIMARY | |||
|
C62514
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
PRIMARY | |||
|
300000011152
Created by
admin on Fri Dec 15 15:29:46 GMT 2023 , Edited by admin on Fri Dec 15 15:29:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD